DCF100

DCF100 is an investigational topical analgesic formulation evaluated in early-phase clinical studies for its ability to reduce UV-induced inflammatory pain in healthy volunteers. It is being compared against other experimental topical analgesics (TIB200 and SPR300), placebo, and active topical reference products in a controlled UV pain model to characterize its pharmacodynamic effects on pain signaling and its local safety and tolerability profile. Publicly available clinical-trial summaries describe DCF100 only as a topical analgesic test product, without disclosing its specific active ingredient(s), molecular target, or detailed mechanism of action.